Helminth Products Potently Modulate Experimental Autoimmune Encephalomyelitis by Downregulating Neuroinflammation and Promoting a Suppressive Microenvironment

Figure 2

TcES foster protection against EAE development with more potency than dexamethasone. The TcES treatment significantly reduced EAE clinical score after a whole clinical course (a). The TcES treatment modulates EAE better than a high dose of dexamethasone (0.3 mg/kg every other day); treatments started 2 days after disease onset (day 10) and continued until sacrifice at the peak of disease (day 26 PI) (b). The TcES modulated disease even when inoculated at a later point in time (day 18 PI, red arrow; normal TcES treatment started at day 12 PI, blue arrow) upon continued treatment until the peak of disease (day 26 PI) (c). Data shown are representative of 2–4 independent experiments. Means and SEM were calculated for a group of mice. The difference between AUC and CDI were calculated by two-tailed ANOVA test and described by the following criteria: and .

(a)

(b)

(c)